The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.

The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 238.98% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.59, which is within the analyst’s predicted range.